JPWO2021237146A5 - - Google Patents
Download PDFInfo
- Publication number
- JPWO2021237146A5 JPWO2021237146A5 JP2022570478A JP2022570478A JPWO2021237146A5 JP WO2021237146 A5 JPWO2021237146 A5 JP WO2021237146A5 JP 2022570478 A JP2022570478 A JP 2022570478A JP 2022570478 A JP2022570478 A JP 2022570478A JP WO2021237146 A5 JPWO2021237146 A5 JP WO2021237146A5
- Authority
- JP
- Japan
- Prior art keywords
- composition
- day
- salt
- 25hc3s
- subject
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000000203 mixture Substances 0.000 claims 21
- PIUZYOCNZPYXOA-ZHHJOTBYSA-N [(3s,8s,9s,10r,13r,14s,17r)-17-[(2r)-6-hydroxy-6-methylheptan-2-yl]-10,13-dimethyl-2,3,4,7,8,9,11,12,14,15,16,17-dodecahydro-1h-cyclopenta[a]phenanthren-3-yl] hydrogen sulfate Chemical compound C1C=C2C[C@@H](OS(O)(=O)=O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@@H](CCCC(C)(C)O)C)[C@@]1(C)CC2 PIUZYOCNZPYXOA-ZHHJOTBYSA-N 0.000 claims 11
- 150000003839 salts Chemical class 0.000 claims 11
- ZGGHKIMDNBDHJB-NRFPMOEYSA-M (3R,5S)-fluvastatin sodium Chemical compound [Na+].C12=CC=CC=C2N(C(C)C)C(\C=C\[C@@H](O)C[C@@H](O)CC([O-])=O)=C1C1=CC=C(F)C=C1 ZGGHKIMDNBDHJB-NRFPMOEYSA-M 0.000 claims 2
- XUKUURHRXDUEBC-KAYWLYCHSA-N Atorvastatin Chemical compound C=1C=CC=CC=1C1=C(C=2C=CC(F)=CC=2)N(CC[C@@H](O)C[C@@H](O)CC(O)=O)C(C(C)C)=C1C(=O)NC1=CC=CC=C1 XUKUURHRXDUEBC-KAYWLYCHSA-N 0.000 claims 2
- XUKUURHRXDUEBC-UHFFFAOYSA-N Atorvastatin Natural products C=1C=CC=CC=1C1=C(C=2C=CC(F)=CC=2)N(CCC(O)CC(O)CC(O)=O)C(C(C)C)=C1C(=O)NC1=CC=CC=C1 XUKUURHRXDUEBC-UHFFFAOYSA-N 0.000 claims 2
- 229940121710 HMGCoA reductase inhibitor Drugs 0.000 claims 2
- PCZOHLXUXFIOCF-UHFFFAOYSA-N Monacolin X Natural products C12C(OC(=O)C(C)CC)CC(C)C=C2C=CC(C)C1CCC1CC(O)CC(=O)O1 PCZOHLXUXFIOCF-UHFFFAOYSA-N 0.000 claims 2
- TUZYXOIXSAXUGO-UHFFFAOYSA-N Pravastatin Natural products C1=CC(C)C(CCC(O)CC(O)CC(O)=O)C2C(OC(=O)C(C)CC)CC(O)C=C21 TUZYXOIXSAXUGO-UHFFFAOYSA-N 0.000 claims 2
- RYMZZMVNJRMUDD-UHFFFAOYSA-N SJ000286063 Natural products C12C(OC(=O)C(C)(C)CC)CC(C)C=C2C=CC(C)C1CCC1CC(O)CC(=O)O1 RYMZZMVNJRMUDD-UHFFFAOYSA-N 0.000 claims 2
- 239000003524 antilipemic agent Substances 0.000 claims 2
- 229960005370 atorvastatin Drugs 0.000 claims 2
- CYQFCXCEBYINGO-IAGOWNOFSA-N delta1-THC Chemical compound C1=C(C)CC[C@H]2C(C)(C)OC3=CC(CCCCC)=CC(O)=C3[C@@H]21 CYQFCXCEBYINGO-IAGOWNOFSA-N 0.000 claims 2
- SSQPWTVBQMWLSZ-AAQCHOMXSA-N ethyl (5Z,8Z,11Z,14Z,17Z)-icosapentaenoate Chemical group CCOC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/C\C=C/CC SSQPWTVBQMWLSZ-AAQCHOMXSA-N 0.000 claims 2
- YMTINGFKWWXKFG-UHFFFAOYSA-N fenofibrate Chemical compound C1=CC(OC(C)(C)C(=O)OC(C)C)=CC=C1C(=O)C1=CC=C(Cl)C=C1 YMTINGFKWWXKFG-UHFFFAOYSA-N 0.000 claims 2
- 229960002297 fenofibrate Drugs 0.000 claims 2
- 235000021323 fish oil Nutrition 0.000 claims 2
- 229960003765 fluvastatin Drugs 0.000 claims 2
- 229960002600 icosapent ethyl Drugs 0.000 claims 2
- 229960004844 lovastatin Drugs 0.000 claims 2
- PCZOHLXUXFIOCF-BXMDZJJMSA-N lovastatin Chemical compound C([C@H]1[C@@H](C)C=CC2=C[C@H](C)C[C@@H]([C@H]12)OC(=O)[C@@H](C)CC)C[C@@H]1C[C@@H](O)CC(=O)O1 PCZOHLXUXFIOCF-BXMDZJJMSA-N 0.000 claims 2
- QLJODMDSTUBWDW-UHFFFAOYSA-N lovastatin hydroxy acid Natural products C1=CC(C)C(CCC(O)CC(O)CC(O)=O)C2C(OC(=O)C(C)CC)CC(C)C=C21 QLJODMDSTUBWDW-UHFFFAOYSA-N 0.000 claims 2
- 208000008338 non-alcoholic fatty liver disease Diseases 0.000 claims 2
- 206010053219 non-alcoholic steatohepatitis Diseases 0.000 claims 2
- 235000020660 omega-3 fatty acid Nutrition 0.000 claims 2
- 229940012843 omega-3 fatty acid Drugs 0.000 claims 2
- 229960002797 pitavastatin Drugs 0.000 claims 2
- VGYFMXBACGZSIL-MCBHFWOFSA-N pitavastatin Chemical compound OC(=O)C[C@H](O)C[C@H](O)\C=C\C1=C(C2CC2)N=C2C=CC=CC2=C1C1=CC=C(F)C=C1 VGYFMXBACGZSIL-MCBHFWOFSA-N 0.000 claims 2
- 229960002965 pravastatin Drugs 0.000 claims 2
- TUZYXOIXSAXUGO-PZAWKZKUSA-N pravastatin Chemical compound C1=C[C@H](C)[C@H](CC[C@@H](O)C[C@@H](O)CC(O)=O)[C@H]2[C@@H](OC(=O)[C@@H](C)CC)C[C@H](O)C=C21 TUZYXOIXSAXUGO-PZAWKZKUSA-N 0.000 claims 2
- 229960000672 rosuvastatin Drugs 0.000 claims 2
- BPRHUIZQVSMCRT-VEUZHWNKSA-N rosuvastatin Chemical compound CC(C)C1=NC(N(C)S(C)(=O)=O)=NC(C=2C=CC(F)=CC=2)=C1\C=C\[C@@H](O)C[C@@H](O)CC(O)=O BPRHUIZQVSMCRT-VEUZHWNKSA-N 0.000 claims 2
- 229960002855 simvastatin Drugs 0.000 claims 2
- RYMZZMVNJRMUDD-HGQWONQESA-N simvastatin Chemical compound C([C@H]1[C@@H](C)C=CC2=C[C@H](C)C[C@@H]([C@H]12)OC(=O)C(C)(C)CC)C[C@@H]1C[C@@H](O)CC(=O)O1 RYMZZMVNJRMUDD-HGQWONQESA-N 0.000 claims 2
- 239000003937 drug carrier Substances 0.000 claims 1
- 238000009472 formulation Methods 0.000 claims 1
- 239000008194 pharmaceutical composition Substances 0.000 claims 1
- 159000000000 sodium salts Chemical class 0.000 claims 1
- 150000003626 triacylglycerols Chemical class 0.000 claims 1
Applications Claiming Priority (9)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202063029364P | 2020-05-22 | 2020-05-22 | |
| US63/029,364 | 2020-05-22 | ||
| US202063030213P | 2020-05-26 | 2020-05-26 | |
| US63/030,213 | 2020-05-26 | ||
| US202063113119P | 2020-11-12 | 2020-11-12 | |
| US63/113,119 | 2020-11-12 | ||
| US202163146556P | 2021-02-05 | 2021-02-05 | |
| US63/146,556 | 2021-02-05 | ||
| PCT/US2021/033746 WO2021237146A1 (en) | 2020-05-22 | 2021-05-21 | Treatment of non-alcoholic steatohepatitis (nash) |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2023526418A JP2023526418A (ja) | 2023-06-21 |
| JPWO2021237146A5 true JPWO2021237146A5 (https=) | 2024-05-28 |
| JP2023526418A5 JP2023526418A5 (https=) | 2024-05-28 |
Family
ID=78707648
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022570478A Pending JP2023526418A (ja) | 2020-05-22 | 2021-05-21 | 非アルコール性脂肪性肝炎（ｎａｓｈ）の処置 |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US20230181602A1 (https=) |
| EP (1) | EP4153165A4 (https=) |
| JP (1) | JP2023526418A (https=) |
| KR (1) | KR20230015940A (https=) |
| CN (1) | CN115803061A (https=) |
| AU (1) | AU2021273937A1 (https=) |
| BR (1) | BR112022023128A2 (https=) |
| CA (1) | CA3183119A1 (https=) |
| MX (1) | MX2022014574A (https=) |
| TW (1) | TW202210082A (https=) |
| WO (1) | WO2021237146A1 (https=) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3494125B1 (en) | 2016-08-02 | 2022-06-22 | Virginia Commonwealth University | Compositions comprising 5-cholesten-3, 25-diol, 3-sulfate (25hc3s) or pharmaceutically acceptable salt thereof and at least one cyclic oligosaccharide |
| KR20260004765A (ko) * | 2024-07-02 | 2026-01-09 | 건국대학교 글로컬산학협력단 | 스타틴이 결합된 담즙산을 포함하는 대사성 질환의 예방 또는 치료용 약학적 조성물 및 이의 제조방법 |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8399441B2 (en) * | 2004-10-25 | 2013-03-19 | Virginia Commonwealth University | Nuclear sulfated oxysterol, potent regulator of lipid homeostasis, for therapy of hypercholesterolemia, hypertriglycerides, fatty liver diseases, and atherosclerosis |
| WO2006047022A1 (en) * | 2004-10-25 | 2006-05-04 | Virginia Commonwealth University | Nuclear sulfated oxysterol, potent regulator of cholesterol homeostasis, for therapy of hypercholesterolemia, hyperlipidemia, and atherosclerosis |
| US9034859B2 (en) * | 2011-04-06 | 2015-05-19 | Virginia Commonwealth University | Sulfated oxysterol and oxysterol sulfation by hydroxysterol sulfotransferase promote lipid homeostasis and liver proliferation |
| SG11201507288UA (en) * | 2013-03-15 | 2015-10-29 | Mochida Pharm Co Ltd | Compositions and methods for treating non-alcoholic steatohepatitis |
| US20200222430A1 (en) * | 2016-08-02 | 2020-07-16 | Durect Corporation | Compositions comprising oxygenated cholesterol sulfate and at least one of polyalkylene glycol, carboxymethyl cellulose and polyoxylglyceride |
| CN110536682B (zh) * | 2017-04-18 | 2023-01-06 | 基恩菲特公司 | 依拉非诺或其衍生物与抗nash、抗纤维化或抗胆汁淤积药剂的组合 |
| KR102419458B1 (ko) * | 2017-10-06 | 2022-07-12 | 길리애드 사이언시즈, 인코포레이티드 | Acc 억제제를 포함하는 조합 요법 |
-
2021
- 2021-05-21 AU AU2021273937A patent/AU2021273937A1/en active Pending
- 2021-05-21 KR KR1020227043977A patent/KR20230015940A/ko active Pending
- 2021-05-21 BR BR112022023128A patent/BR112022023128A2/pt not_active Application Discontinuation
- 2021-05-21 US US17/924,103 patent/US20230181602A1/en active Pending
- 2021-05-21 CA CA3183119A patent/CA3183119A1/en active Pending
- 2021-05-21 EP EP21809835.8A patent/EP4153165A4/en active Pending
- 2021-05-21 WO PCT/US2021/033746 patent/WO2021237146A1/en not_active Ceased
- 2021-05-21 CN CN202180049250.2A patent/CN115803061A/zh active Pending
- 2021-05-21 JP JP2022570478A patent/JP2023526418A/ja active Pending
- 2021-05-21 TW TW110118459A patent/TW202210082A/zh unknown
- 2021-05-21 MX MX2022014574A patent/MX2022014574A/es unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| KR101465717B1 (ko) | 심혈관 이벤트 발병 예방용 조성물 | |
| KR20080070089A (ko) | 콜레스테롤 흡수 억제제, ＨＭＧ-ＣｏＡ 리덕타제 억제제및 안정화제를 포함하는 조성물 | |
| US6673831B1 (en) | Combination therapy for reducing the risks associated with cardiovascular disease | |
| WO1997038694A1 (en) | Combination therapy for reducing the risks associated with cardiovascular disease | |
| CN1330544A (zh) | 色伐他丁与贝特的组合 | |
| CA2456732A1 (en) | Oral pharmaceutical composition containing a combination of ppar.alpha. and a hmg-coa reductase inhibitor | |
| IL274414B2 (en) | Oral rifamycin sv compositions | |
| US20140314844A1 (en) | Oral complex formulation comprising omega-3 fatty acid and hmg-coa reductase inhibitor with improved stability | |
| JP2009515816A (ja) | フェノフィブレートおよびスタチンを含んでなる新規調合物、ならびに関連する処置方法 | |
| US20050187204A1 (en) | Medicinal composition for lowering blood lipid level | |
| JPWO2021237146A5 (https=) | ||
| US6890941B1 (en) | Compositions containing HMG Co-A reductase inhibitors and policosanol | |
| AU2005314197A1 (en) | Stable compositions of fenofibrate with fatty acid esters | |
| TWI302457B (en) | A pharmaceutical composition for improving blood lipid or reducing blood homocysteine | |
| JPWO2021237143A5 (https=) | ||
| WO2020028124A1 (en) | NEW USE OF CARBAMATE β PHENYLETHANOLAMINE ANALOGUES FOR ENHANCING INTRACELLULAR CLEARANCE OF LDL CHOLESTEROL AND FOR COMBINING THERAPY WITH STATINS TO ENHANCE THE EFFICACY AND REDUCE ADVERSE EFFECTS | |
| KR100725263B1 (ko) | ＨＭＧ-ＣｏＡ 리덕타제 억제제 및 카르니틴을 포함하는 항지질혈성 복합제 | |
| RU2007149337A (ru) | Новый способ лечения гиперлипидемии | |
| Sodipo et al. | Drug therapy for hyperlipidaemia (dyslipidaemia)-A review | |
| KR101830977B1 (ko) | 오메가-3 지방산 또는 이의 에스테르 및 하이드록시메틸글루타닐 코엔자임에이 환원효소 억제제를 포함하는 경구용 복합 제제 | |
| Efthimiadis et al. | 2. P. 30 Effect of fluvastatin on coagulant-fibrinolytic system in patients with coronary artery disease | |
| KR101954568B1 (ko) | 오메가-3 지방산 또는 이의 에스테르 및 하이드록시메틸글루타닐 코엔자임에이 환원효소 억제제를 포함하는 경구용 복합 제제 | |
| KR20130003501A (ko) | 오메가-3 지방산 또는 이의 에스테르 및 하이드록시메틸글루타닐 코엔자임에이 환원효소 억제제를 포함하는 경구용 복합 제제 | |
| HK1080384B (en) | Composition comprising a cholesterol absorption inhibitor, an hmg-coa reductase inhibitor and a stabilizing agent | |
| CN105030727A (zh) | 洛伐他汀胶囊及其生产工艺 |